IP Verse

Ucb Pharma competitive analysis

Latest publications and patents of Ucb Pharma New

Explore the latest publications and patents granted to Ucb Pharma, showcasing their recent innovations and technological advancements.

Last updated on: Sep 24, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Ucb Pharma

EP2301961
Dec 13, 2023Sclerostin EpitopesPatent Maintained As Amended
EP3145504
Jul 26, 2023Transdermal Delivery System Including An Interface MediatorGranted And Under Opposition
EP2869844
Jun 21, 2023Treatment For Bone DiseasesPatent Maintained As Amended
EP2645997
Aug 10, 2022Once Daily Formulation Of LacosamideRevoked
EP2345668
Sep 22, 2021Sclerostin EpitopesGranted And Under Opposition
EP3670528
Sep 8, 2021Sclerostin Binding AgentsGranted And Under Opposition
EP2992891
Aug 5, 2020Pharmaceutical Composition Comprising Brivaracetam And Lacosamide With Synergistic Anticonvulsant EffectGranted And Under Opposition
EP2515887
Jun 6, 2018Polyvinylpyrrolidone For The Stabilization Of A Solid Dispersion Of The Non-Crystalline Form Of RotigotineOpposition Rejected
EP2475682
Jan 31, 2018Multivalent AntibodiesNo Opposition Filed Within Time Limit
EP2535350
Jan 24, 2018Dual Specificity Antibody FusionsNo Opposition Filed Within Time Limit

Latest oppositions filed by Ucb Pharma

Explore patent oppositions filed by Ucb Pharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 25, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3345607
Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or AgonistOSSIFI MABJul 26, 2023

Latest patents of Ucb Pharma opposed by its competitors

Explore Ucb Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2301961
Dec 13, 2023Sclerostin Epitopes1
EP3145504
Jul 26, 2023Transdermal Delivery System Including An Interface Mediator1
EP2869844
Jun 21, 2023Treatment For Bone Diseases1
EP2645997
Aug 10, 2022Once Daily Formulation Of Lacosamide1
EP2345668
Sep 22, 2021Sclerostin Epitopes1
EP3670528
Sep 8, 2021Sclerostin Binding Agents1
EP2992891
Aug 5, 2020Pharmaceutical Composition Comprising Brivaracetam And Lacosamide With Synergistic Anticonvulsant Effect1
EP2515887
Jun 6, 2018Polyvinylpyrrolidone For The Stabilization Of A Solid Dispersion Of The Non-Crystalline Form Of Rotigotine2
EP2037965
Aug 30, 2017Pharmaceutical Composition With Synergistic Anticonvulsant Effect1
EP2922533
Jun 14, 2017Multi-Day Patch For The Transdermal Administration Of Rotigotine2

Latest PTAB cases involving Ucb Pharma

Discover the latest PTAB cases involving Ucb Pharma, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 30, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Ucb Pharma

IPR2016-01665Aug 22, 2016AMERIGEN PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-01596Aug 22, 2016ALEMBIC PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-01636Aug 18, 2016TORRENT PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-00517Jan 28, 2016MYLAN PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-00516Jan 28, 2016MYLAN PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-00514Jan 28, 2016MYLAN PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-00512Jan 28, 2016MYLAN PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-00510Jan 28, 2016MYLAN PHARMACEUTICALSUCB PHARMAFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Ucb Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
UCB PHARMA - 12 - 8Non-Active
ALEMBIC PHARMACEUTICALS - - 2 - Highly Aggressive
JAMES POOLE151 - - - Highly Aggressive
MYLAN PHARMACEUTICALS - - 94 - Highly Aggressive